THE PROPOSED MECHANISM
How Does PP405 Work?
PP405 is proposed to work through metabolism rather than hormones: by inhibiting the mitochondrial pyruvate carrier in hair-follicle stem cells, it may shift their metabolic state toward the configuration associated with activation. This is a research model — presented here with its evidence labels attached, not as established human biology.
- 1
Extracellular nutrient availability
Follicle stem cells sit in a nutrient environment whose glucose supply feeds glycolysis — the raw material of the metabolic decision.
- 2
Pyruvate metabolism
Glycolysis produces pyruvate, which stands at a fork: mitochondrial oxidation or cytosolic conversion to lactate.
- 3
The mitochondrial pyruvate-carrier pathway
The carrier is the gate. Inhibiting it — the PP405 mechanism class — diverts pyruvate away from mitochondria and toward lactate production.
- 4
The metabolic state of hair-follicle stem cells
Published mouse research links the lactate-producing configuration to the activation-prone stem-cell state.
- 5
Dormancy toward an active hair-cycle state
The investigational question: whether shifting that metabolic state supports a transition from follicular dormancy toward an active hair cycle. Under third-party clinical investigation — not established.
Why glycolysis and lactate matter in the follicle
Most adult stem cells are thought to keep oxidative metabolism low while quiescent, but hair-follicle stem cells go further: they are markedly glycolytic and produce substantially more lactate than surrounding epidermal cells. Flores and colleagues showed that this is functional, not incidental — deleting lactate dehydrogenase in the stem-cell compartment blocked activation, while genetically pushing the cells toward lactate production (by deleting the mitochondrial pyruvate carrier) accelerated it.[2]
In other words, the lactate-producing metabolic state is part of how a follicle stem cell leaves dormancy. A compound that biases the cell toward that state is therefore a rational research tool — and, in mouse models including age-, chemotherapy- and stress-driven alopecia, carrier inhibition did accelerate the hair cycle.[3]
How strong is the mechanism evidence?
In animals: strong and peer-reviewed — convergent genetic and pharmacological evidence in mice. In humans: early and company-reported — a Phase 2a trial that was designed primarily around tolerability and pharmacokinetics, with exploratory density findings the developer itself describes as preliminary.[5]
The honest summary: the mechanism is a well-supported animal model and a plausible human hypothesis. It requires further clinical validation through larger controlled trials, and it says nothing about any formulation other than the developer’s own.
What the mechanism does not establish
- It does not establish that PP405 reactivates dormant human follicles — that is the Phase 3 question.
- It does not establish durable regrowth, cosmetically meaningful density, or benefit across populations.
- It does not establish anything about Pelogen™: no Pelogen™ formulation has entered any biological study.
- It does not make PP405 an approved or available treatment anywhere.
Continue to PP405 hair regrowth research, the scientific source library, the research status page, the Pelogen™ overview or Panacea Bio Chem ↗.